MRNA MANUFACTURING: BRIGHT FUTURE, BIG CHALLENGES

• mRNA Manufacturing: Bright Future, Big Challenges

  While the rapid development of effective mRNA vaccines demonstrates the potential of the technology's breadth, speed, and scale, manufacturing hurdles and bottlenecks remain. Join us for an interactive panel discussion with biopharma executives on the front lines of the quest to develop the manufacturing efficiencies required to enable the prophylactic and therapeutic potential of mRNA technology.

BIOPROCESS AUTOMATION: TRUTH OR ILLUSION?

• Bioprocess Automation: Truth Or Illusion?

  iBio COO Randy Maddux, Kyowa Kirin, EVP of Operations and Supply Chain Paul Testa, and Sutro Biopharma VP of Manufacturing and Plant Operations Devendra Luhar joined Matt Pillar, Chief Editor of Bioprocess Online for a spirited, interactive discussion on aversions to biopharma manufacturing automation, the technology, cost, and implementation challenges it presents, and why you should commit to it anyway.  Actionable insights include the stepwise, cost-conscious approaches the panelists are taking to improving quality control and data integrity through automation. 

UPSTREAM PROCESS INTENSIFICATION: REAL-WORLD RESULTS

• Upstream Process Intensification: Real-World Results

  Join Sonnet BioTherapeutics CTO Susan Dexter, single-use/process intensification pioneer Parrish Galliher, and Matt Pillar for an in-depth discussion on upstream process intensification in practice.

• Why Invest In Process Intensification?
• Supplier Qualification & Cost Of Perfusion Intensification
• Process Intensification: ROI Realities & Implementation Considerations
• Regulatory Considerations For Process Intensification

GENE & RNA THERAPIES: REGULATORY REQUIREMENTS TAKE SHAPE

• Gene & RNA Therapies: Regulatory Requirements Take Shape

  Unprecedented progress in advanced therapy medicinal product development platforms leveraging AAV, mRNA, and oligonucleotide technologies are testing the mettle of biopharmas and regulatory bodies alike. Check out our On-Demand presentation of BioProcess Online Live - Gene & RNA Therapies: Regulatory Requirements Take Shape. Learn how to form up your own regulatory strategy, align your data with the most current FDA guidance, and develop a mutually-beneficial relationship with regulators in this interactive discussion with executives on the front lines of emerging ATMP regulatory requirements.

• Forming Up A Regulatory Strategy: When And How To Start
• Regulating Personalized Therapeutics: Are There Precedents?
• Accommodating The FDA: Handling Change Management In Your Regulatory Strategy
• FDA Regulations: What's Guidance, What Are Requirements, & What Matters Most?

VACCINE MANUFACTURING & REGULATORY ADVANCES: RIDING COVID'S COATTAILS

• Vaccine Manufacturing & Regulatory Advances: Riding COVID's Coattails

  Accelerated by the COVID-19 pandemic, nucleic acid, viral vector-based, inactivated, and other vaccine tech targeting a host of disease states are experiencing a rapid resurgence among biopharmas large and small. Learn how next-generation vaccine manufacturers are changing the egg yolk manufacturing paradigm and seizing an unprecedented regulatory momentum.

• Today's Biggest Vaccine Manufacturing Challenges
• Vaccine Platforms & Platform Variables
• Will Biopharma Regulators Maintain Their Accelerated Pace?
• Post-COVID Biopharma Regulatory Reactions

TACKLING THE CELL & GENE MANUFACTURING TALENT CRUNCH

• Tackling The Cell & Gene Manufacturing Talent Crunch

  Join Project Farma and Precision ADVANCE leaders Anshul Mangal and John Khoury for a discussion with BioProcess Online Chief Editor Matt Pillar to address solutions to the biotherapeutic and cell and gene therapy process and manufacturing talent gap.

BIOPHARMA'S TOP TRENDS 2020 - PROGRESS, ACCELERATED - LOOKING TOWARD 2021

• Biopharma's Top Trends 2020 - Progress, Accelerated - Looking Toward 2021

  BioProcess Online hosted a presentation on the biopharma trends that will continue impacting your facility and business in 2021—and how to address them—with BioPlan Associates, Inc.’ Eric Langer and Fujifilm Diosynth Biotechnologies’ Jonathan M Haigh, Ph.D.

• Cell & Gene Therapy Capacity Crunch
• Bioprocessing Manufacturing Productivity, Single Use Displaces Stainless In 2021
• Biopharma’s Response To The Covid-19 Pandemic